Aion Medicines, a subsidiary of Exavir Therapeutics, announced the presentation of preclinical data for AM-710, the company's ultra-long-acting small molecule GLP1R agonist, at the ObesityWeek ...
U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue -As of October 25, 2025, 5,259 unique patient prescriptions have been written by ...
The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...
An artificial intelligence model predicts how brain immune cells react to RNA and DNA nanoparticles, helping scientists design safer and more effective nucleic acid therapies faster.
Good afternoon, and welcome to Sarepta's Third Quarter 2025 Financial Results Conference Call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, ...
New research posits that a genetic incompatibility between female offspring of humans and Neanderthals and their children ...
Than Powell Than Powell, CBO, Longeveron On track for top-line trial results in the third quarter of 2026 from pivotal Phase ...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, ...
A Czech scientist has contributed to understanding the function of the thymus—the training center of the immune system. T ...
The microbiome—the trillions of bacteria, viruses, and fungi that live quietly in our body—plays a crucial role in shaping human health by providing a variety of micronutrients necessary for vital ...
New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback